Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The pri...
Saved in:
| Published in | PloS one Vol. 13; no. 9; p. e0203054 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
07.09.2018
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers.
Thirty subjects (13 females, 46-71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates.
There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively.
8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. |
|---|---|
| AbstractList | Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers. Thirty subjects (13 females, 46-71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates. There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively. 8 mg.kg.sup.-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers. Materials and methods Thirty subjects (13 females, 46–71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates. Results There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively. Conclusions 8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers. Materials and methods Thirty subjects (13 females, 46–71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates. Results There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively. Conclusions 8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers. Materials and methods Thirty subjects (13 females, 46-71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates. Results There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively. Conclusions 8 mg.kg.sup.-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers. Thirty subjects (13 females, 46-71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates. There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively. 8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers.BACKGROUNDGiven the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02 (galactoarabino-rhamnogalaturonate) has been shown to reduce hepatic fibrosis in animal studies, and lower serum biomarkers of NASH fibrogenesis in humans. The primary aim of this study was to determine the difference between four-months of treatment with GR-MD-02 or placebo in liver inflammation and fibrosis as measured by iron-corrected T1 (cT1) mapping, a non-invasive magnetic resonance imaging (MRI) biomarker that correlates with the extent of hepatic fibro-inflammatory disease. The secondary aims were to determine change in liver stiffness as measured by magnetic resonance elastography (MRE) and shear-wave ultrasonic elastography (LSM), and to explore test-retest repeatability of the three biomarkers.Thirty subjects (13 females, 46-71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates.MATERIALS AND METHODSThirty subjects (13 females, 46-71 years) with NASH and advanced fibrosis were recruited. Subjects were randomized to receive 8 mg.kg-1 GR-MD-02 (via IV infusion) or placebo, administered biweekly over a 16-week period. Therapeutic efficacy was examined using cT1, MRE, and LSM. Statistical analyses on group differences in the biomarkers were performed using robust ANCOVA models adjusting for baseline measurement and additional covariates.There was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively.RESULTSThere was no significant difference in cT1 (p = 0.16) between GR-MD-02 and placebo groups following a 16-week intervention. There was also no significant difference in liver stiffness, measured by MRE (p = 0.80) or LSM (p = 0.63), between groups. Examination of repeatability of the cT1, MRE and LSM revealed coefficient of variations of 3.1%, 11% and 40% respectively.8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH.CONCLUSIONS8 mg.kg-1 of GR-MD-02 had no significant effect on non-invasive biomarkers of liver inflammation or fibrosis over a 4-month period. Histological confirmation was not available in this study. The high reproducibility of the primary outcome measure suggests that cT1 could be utilized for monitoring longitudinal change in patients with NASH. |
| Audience | Academic |
| Author | Dennis, Andrea Traber, Peter G. Kelly, Matt D. Kelly, Catherine J. Neubauer, Stefan Whitehead, Jennifer M. Harrison, Stephen A. Fiore, Martine M. Paredes, Angelo H. Banerjee, Rajarshi |
| AuthorAffiliation | 3 San Antonio Military Medical Center, San Antonio, Texas, United States of America Kaohsiung Medical University, TAIWAN 2 Perspectum Diagnostics, Oxford, United Kingdom 1 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom 4 Galectin Therapeutics Incorporated, Norcross, Georgia, United States of America |
| AuthorAffiliation_xml | – name: 2 Perspectum Diagnostics, Oxford, United Kingdom – name: 3 San Antonio Military Medical Center, San Antonio, Texas, United States of America – name: 1 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom – name: Kaohsiung Medical University, TAIWAN – name: 4 Galectin Therapeutics Incorporated, Norcross, Georgia, United States of America |
| Author_xml | – sequence: 1 givenname: Stephen A. surname: Harrison fullname: Harrison, Stephen A. – sequence: 2 givenname: Andrea orcidid: 0000-0002-0152-6528 surname: Dennis fullname: Dennis, Andrea – sequence: 3 givenname: Martine M. surname: Fiore fullname: Fiore, Martine M. – sequence: 4 givenname: Matt D. surname: Kelly fullname: Kelly, Matt D. – sequence: 5 givenname: Catherine J. surname: Kelly fullname: Kelly, Catherine J. – sequence: 6 givenname: Angelo H. surname: Paredes fullname: Paredes, Angelo H. – sequence: 7 givenname: Jennifer M. surname: Whitehead fullname: Whitehead, Jennifer M. – sequence: 8 givenname: Stefan surname: Neubauer fullname: Neubauer, Stefan – sequence: 9 givenname: Peter G. surname: Traber fullname: Traber, Peter G. – sequence: 10 givenname: Rajarshi surname: Banerjee fullname: Banerjee, Rajarshi |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30192782$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tu1DAQhiNURA_wBggsISG4yOJDYidcIFUF2kqFSi3l1nJsZ9crr73YzkJ5QV4L76FVt6oQipRknO__Zzzx7Bc7zjtdFM8RHCHC0LupH4ITdjTPyyOIIYF19ajYQy3BJc3hzp333WI_ximENWkofVLsEohazBq8V_y5SsaadA2EU2AhghHdOvY9SJOgNchpS-MWIpqFBjbfAuhNF3w0EZiZGBs3BjOvRFYZHUHyQC-EHUTSQPe9kUKuzI4vyi8fS4iBcSAO3VTLFMFPkybg6-HlySp9F4xa2d36qyEsYwHmExF1iUHInJ-Z31oBaY3L7hakXLR9WjzuhY362eZ5UFx9_vTt6KQ8Oz8-PTo8KyVtcSolYVJQLZuqowS2jBHFlOqgErphNWsorhGraNdJgjuIG9o2jSQ97LVCDDJMDoqXa9-59ZFv_kHkGEHYUFS3JBOna0J5MeXzkHsUrrkXhq8WfBhzEZKRVvNKEN10GreqYlVLSdPl2lCtJKEMVX2VvT5ssg3dTCupXQrCbpluf3Fmwsd-wSnCTfbMBm82BsH_GHRMfGai1NYKp_2wqhthSptV3a_uoQ_vbkONRd6Acb3PeeXSlB_WNWMtYqzO1OgBKl9Kz4zMB7Y3eX1L8HZLkJmkf6WxGGLkp5cX_8-ef99mX99hJ1rYNIneDsl4F7fBF3c7fdvim0nJQLUGZD6aMej-FkGQLwfypl18OZB8M5BZ9v6eTJoklulzR4z9t_gvfHQ9wA |
| CitedBy_id | crossref_primary_10_3748_wjg_v27_i7_609 crossref_primary_10_1016_j_jhep_2020_03_032 crossref_primary_10_1111_liv_14625 crossref_primary_10_3390_biomedicines9091159 crossref_primary_10_1016_j_ejrad_2024_111749 crossref_primary_10_1038_s41598_020_71995_8 crossref_primary_10_3179_jjmu_JJMU_R_203 crossref_primary_10_1007_s00261_020_02684_3 crossref_primary_10_1016_j_coph_2019_09_006 crossref_primary_10_3389_fmed_2021_656658 crossref_primary_10_1038_s41598_024_77307_8 crossref_primary_10_1080_14728214_2020_1735350 crossref_primary_10_1080_14728222_2023_2258280 crossref_primary_10_1097_MPG_0000000000002930 crossref_primary_10_1038_s43856_025_00796_9 crossref_primary_10_4292_wjgpt_v15_i6_97381 crossref_primary_10_1016_j_metabol_2022_155264 crossref_primary_10_1016_j_eclinm_2022_101325 crossref_primary_10_1002_mrm_28970 crossref_primary_10_1016_j_cgh_2021_09_041 crossref_primary_10_1111_jgh_16559 crossref_primary_10_2196_19189 crossref_primary_10_14336_AD_2021_1105 crossref_primary_10_2214_AJR_22_27676 crossref_primary_10_3390_cancers15194863 crossref_primary_10_1002_edm2_134 crossref_primary_10_1039_D3TB02790B crossref_primary_10_1007_s10396_020_01059_x crossref_primary_10_1016_j_ebiom_2019_05_025 crossref_primary_10_3390_ijms24098116 crossref_primary_10_1038_s41467_021_25701_5 crossref_primary_10_3390_ijms24076501 crossref_primary_10_14218_JCTH_2020_00040 crossref_primary_10_1016_j_acra_2021_09_018 crossref_primary_10_1016_j_mce_2019_02_005 crossref_primary_10_1136_bmjopen_2021_058999 crossref_primary_10_1007_s40265_020_01458_x crossref_primary_10_3389_fphar_2022_973366 crossref_primary_10_1007_s00261_020_02656_7 crossref_primary_10_1007_s12664_020_01021_2 crossref_primary_10_1007_s00261_019_02382_9 crossref_primary_10_1080_14728214_2021_1918099 crossref_primary_10_3389_fendo_2020_575843 crossref_primary_10_1007_s00261_020_02860_5 crossref_primary_10_1016_j_freeradbiomed_2020_09_008 crossref_primary_10_1016_j_ejim_2020_06_004 crossref_primary_10_1002_poh2_6 crossref_primary_10_3389_fphar_2022_874408 crossref_primary_10_1038_s41598_024_67843_8 crossref_primary_10_1007_s10719_024_10152_z crossref_primary_10_1016_j_metabol_2020_154203 crossref_primary_10_1016_j_cgh_2019_12_013 crossref_primary_10_3389_fmed_2021_615978 crossref_primary_10_1155_2021_6612892 crossref_primary_10_1016_j_molmed_2024_11_006 crossref_primary_10_1016_j_biocel_2020_105881 crossref_primary_10_1016_j_jbc_2022_102622 |
| Cites_doi | 10.1186/1471-230X-6-6 10.1371/journal.pone.0075361 10.1002/hep.25762 10.1016/j.cgh.2014.09.046 10.1053/j.gastro.2010.09.038 10.1002/hep.27647 10.1021/bi201121m 10.1002/hep.23425 10.1016/S0973-6883(12)60103-0 10.1038/s41598-018-27560-5 10.1016/j.jhep.2013.09.002 10.1002/hep.26455 10.1016/j.jhep.2011.01.051 10.1016/S0168-8278(18)30420-3 10.1111/apt.13816 10.1371/journal.pone.0083481 10.1111/apt.13405 10.1016/j.jacc.2016.03.597 10.1016/j.jhep.2014.04.044 10.1016/j.jhep.2016.06.005 10.2165/00003088-200544100-00004 10.1136/heartjnl-2012-303052 10.1002/jmri.25392 10.1002/hep.24634 10.1002/hep.28012 10.1007/s00330-013-3046-0 10.1038/srep40977 10.1111/liv.13284 10.1002/hep.20701 10.1016/j.jhep.2017.11.028 10.1016/j.jhep.2013.12.016 10.4254/wjh.v7.i9.1192 10.1182/blood-2004-10-3982 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Public Library of Science This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2018 Public Library of Science – notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0203054 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ : directory of open access journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine |
| DocumentTitleAlternate | Utility and variability of three non-invasive liver fibrosis imaging modalities |
| EISSN | 1932-6203 |
| ExternalDocumentID | 2100861593 oai_doaj_org_article_4a3e8be29d4749638ba6e15dc36714f4 PMC6128474 A557791775 30192782 10_1371_journal_pone_0203054 |
| Genre | Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK United States--US Texas |
| GeographicLocations_xml | – name: Texas – name: United Kingdom--UK – name: United States--US |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PQEST PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c692t-c37ca6ec84b6309773d7ddb0dae875786251746bbc32b0286988c3f0fed170723 |
| IEDL.DBID | 7X7 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:13:47 EST 2021 Wed Aug 27 01:21:42 EDT 2025 Thu Aug 21 13:30:02 EDT 2025 Fri Jul 11 11:12:31 EDT 2025 Fri Jul 25 11:22:27 EDT 2025 Tue Jun 17 21:08:41 EDT 2025 Tue Jun 10 20:28:34 EDT 2025 Fri Jun 27 03:34:33 EDT 2025 Fri Jun 27 04:57:05 EDT 2025 Thu May 22 21:21:32 EDT 2025 Wed Feb 19 02:29:16 EST 2025 Thu Apr 24 23:10:38 EDT 2025 Thu Jul 10 07:51:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Creative Commons CC0 public domain |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-c37ca6ec84b6309773d7ddb0dae875786251746bbc32b0286988c3f0fed170723 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Competing Interests: We have the following interests. Peter G. Traber is CEO and CMO of Galectin Therapeutics Inc., the study sponsor. Stefan Neubauer is shareholder and non-executive director of Perspectum Diagnostics; Rajarshi Banerjee is shareholder and CEO of Perspectum Diagnostics; Stephen A. Harrison is a consultant for Perspectum Diagnostics and Galectin Therapeutics Inc; AD, MMF, MDK and CJK are all employees of Perspectum Diagnostics who were responsible for the blinded analysis of the LiverMultiScan data. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. |
| ORCID | 0000-0002-0152-6528 |
| OpenAccessLink | https://www.proquest.com/docview/2100861593?pq-origsite=%requestingapplication% |
| PMID | 30192782 |
| PQID | 2100861593 |
| PQPubID | 1436336 |
| PageCount | e0203054 |
| ParticipantIDs | plos_journals_2100861593 doaj_primary_oai_doaj_org_article_4a3e8be29d4749638ba6e15dc36714f4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6128474 proquest_miscellaneous_2101266893 proquest_journals_2100861593 gale_infotracmisc_A557791775 gale_infotracacademiconefile_A557791775 gale_incontextgauss_ISR_A557791775 gale_incontextgauss_IOV_A557791775 gale_healthsolutions_A557791775 pubmed_primary_30192782 crossref_primary_10_1371_journal_pone_0203054 crossref_citationtrail_10_1371_journal_pone_0203054 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-09-07 |
| PublicationDateYYYYMMDD | 2018-09-07 |
| PublicationDate_xml | – month: 09 year: 2018 text: 2018-09-07 day: 07 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2018 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | I Doycheva (ref35) 2016; 43 JC Wood (ref16) 2005; 106 M Rinella (ref4) 2011; 54 R Loomba (ref34) 2018; 68 P Bannas (ref30) 2015; 62 C Cassinotto (ref23) 2014; 61 DE Kleiner (ref26) 2005; 41 HK Lückhoff (ref33) 2015; 7 S Caldwell (ref3) 2010; 28 P Traber (ref6) 2013; 8 M Noureddin (ref29) 2013; 58 N McDonald (ref10) 2018; 8 SK Asrani (ref24) 2014; 60 N Chalasani (ref37) 2018; 68 EM Tunnicliffe (ref18) 2017; 45 CR Bradley (ref12) 2018 R Loomba (ref36) 2015; 61 A Hall (ref15) 2017; 7 A Arora (ref32) 2012; 2 S Harrison (ref8) 2016; 44 V Ratziu (ref9) 2006; 6 CD Williams (ref2) 2011; 140 E Levelt (ref11) 2016; 68 PS Dulai (ref31) 2016; 65 MA Robic (ref22) 2011; 55 R Banerjee (ref17) 2014; 61 (ref28) 2017 N Chalasani (ref1) 2012; 55 L Castera (ref25) 2010; 51 S Singh (ref21) 2015; 13 S Janmahasatian (ref27) 2005; 44 S Bull (ref13) 2013; 99 S Di Lella (ref5) 2011; 50 M Pavlides (ref19) 2017; 37 VM Ferreira (ref14) 2014; 16 AE Bohte (ref20) 2014; 24 P Traber (ref7) 2013; 8 |
| References_xml | – volume: 6 start-page: 6 issue: 1 year: 2006 ident: ref9 article-title: Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease publication-title: BMC Gastroenterol doi: 10.1186/1471-230X-6-6 – volume: 8 issue: 10 year: 2013 ident: ref7 article-title: Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease publication-title: PLoS One doi: 10.1371/journal.pone.0075361 – volume: 55 start-page: 2005 issue: 6 year: 2012 ident: ref1 article-title: The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association publication-title: Hepatology doi: 10.1002/hep.25762 – volume: 13 start-page: 440 year: 2015 ident: ref21 article-title: Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2014.09.046 – year: 2017 ident: ref28 article-title: R: A language and environment for statistical computing – volume: 140 start-page: 124 issue: 1 year: 2011 ident: ref2 article-title: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle- aged population utilizing ultrasound and liver biopsy: a prospective study publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.09.038 – volume: 61 start-page: 1239 issue: 4 year: 2015 ident: ref36 article-title: Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) publication-title: Hepatology doi: 10.1002/hep.27647 – volume: 50 start-page: 7842 issue: 37 year: 2011 ident: ref5 article-title: When galectins recognize glycans: from biochemistry to physiology and back again publication-title: Biochemistry doi: 10.1021/bi201121m – volume: 51 start-page: 828 issue: 3 year: 2010 ident: ref25 article-title: Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations publication-title: Hepatology doi: 10.1002/hep.23425 – volume: 2 start-page: 145 issue: 2 year: 2012 ident: ref32 article-title: Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease publication-title: J Clin Exp Hepatol doi: 10.1016/S0973-6883(12)60103-0 – volume: 8 start-page: 9189 issue: 1 year: 2018 ident: ref10 article-title: Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study publication-title: Sci Rep doi: 10.1038/s41598-018-27560-5 – volume: 61 start-page: 69 issue: 1 year: 2014 ident: ref17 article-title: Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2013.09.002 – volume: 58 start-page: 1930 issue: 6 year: 2013 ident: ref29 article-title: Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials publication-title: Hepatology doi: 10.1002/hep.26455 – volume: 55 start-page: 1017 year: 2011 ident: ref22 article-title: Métivier S, Péron JM, Selves J VJ. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study publication-title: J Hepatol doi: 10.1016/j.jhep.2011.01.051 – volume: 68 start-page: S100 issue: Supplement 1 year: 2018 ident: ref37 article-title: A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension publication-title: J Hepatol doi: 10.1016/S0168-8278(18)30420-3 – volume: 44 start-page: 1183 issue: 11–12 year: 2016 ident: ref8 article-title: Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13816 – volume: 8 issue: 12 year: 2013 ident: ref6 article-title: Therapy of experimental NASH and fibrosis with galectin inhibitors publication-title: PLoS One doi: 10.1371/journal.pone.0083481 – volume: 43 start-page: 83 issue: 1 year: 2016 ident: ref35 article-title: Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13405 – volume: 68 start-page: 53 issue: 1 year: 2016 ident: ref11 article-title: Ectopic and Visceral Fat Deposition in Lean and Obese Patients with Type 2 Diabetes publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2016.03.597 – volume: 61 start-page: 550 year: 2014 ident: ref23 article-title: Non- invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R) publication-title: J Hepatol doi: 10.1016/j.jhep.2014.04.044 – volume: 65 start-page: 1006 issue: 6 year: 2016 ident: ref31 article-title: MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice publication-title: J Hepatol doi: 10.1016/j.jhep.2016.06.005 – volume: 44 start-page: 1051 issue: 10 year: 2005 ident: ref27 article-title: Quantification of lean bodyweight publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200544100-00004 – volume: 16 start-page: 1 issue: 1 year: 2014 ident: ref14 article-title: Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents – volume: 99 start-page: 932 issue: 13 year: 2013 ident: ref13 article-title: Human non-contrast T1 values and correlation with histology in diffuse fibrosis publication-title: Heart doi: 10.1136/heartjnl-2012-303052 – volume: 45 start-page: 450 issue: 2 year: 2017 ident: ref18 article-title: A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1 (shMOLLI-T1) in the liver publication-title: J Magn Reson Imaging doi: 10.1002/jmri.25392 – year: 2018 ident: ref12 article-title: Multi organ assessment of Compensated Cirrhosis Patients using quantitative Magnetic Resonance Imaging publication-title: J Hepatol – volume: 54 start-page: 1118 issue: 4 year: 2011 ident: ref4 article-title: Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? publication-title: Hepatology doi: 10.1002/hep.24634 – volume: 28 start-page: 62 issue: 1 year: 2010 ident: ref3 article-title: The natural history of non-alcoholic fatty liver disease publication-title: Dig Dis Sci – volume: 62 start-page: 1444 issue: 5 year: 2015 ident: ref30 article-title: Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers publication-title: Hepatology doi: 10.1002/hep.28012 – volume: 24 start-page: 638 issue: 3 year: 2014 ident: ref20 article-title: Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C publication-title: Eur Radiol doi: 10.1007/s00330-013-3046-0 – volume: 7 start-page: 40977 year: 2017 ident: ref15 article-title: Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis publication-title: Sci Rep doi: 10.1038/srep40977 – volume: 37 start-page: 1065 issue: 7 year: 2017 ident: ref19 article-title: Multi-parametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity publication-title: Liver Int doi: 10.1111/liv.13284 – volume: 41 start-page: 1313 issue: 6 year: 2005 ident: ref26 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.20701 – volume: 68 start-page: 296 issue: 2 year: 2018 ident: ref34 article-title: Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions publication-title: J Hepatol doi: 10.1016/j.jhep.2017.11.028 – volume: 60 start-page: 934 year: 2014 ident: ref24 article-title: Role of magnetic resonance elastography in compensated and decompen- sated liver disease publication-title: J Hepatol doi: 10.1016/j.jhep.2013.12.016 – volume: 7 start-page: 1192 issue: 9 year: 2015 ident: ref33 article-title: Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries publication-title: World J Hepatol doi: 10.4254/wjh.v7.i9.1192 – volume: 106 start-page: 1460 issue: 4 year: 2005 ident: ref16 article-title: MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients publication-title: Blood doi: 10.1182/blood-2004-10-3982 |
| SSID | ssj0053866 |
| Score | 2.5125458 |
| Snippet | Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02... Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02... BACKGROUND:Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02... Background Given the worldwide prevalence of NAFLD and NASH, there is a need to develop treatments to slow or reverse disease progression. GR-MD-02... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0203054 |
| SubjectTerms | Aged Anti-inflammatory agents Biology and Life Sciences Biomarkers Care and treatment Clinical trials Collagen Dosage and administration Double-Blind Method Drug dosages Elasticity Fatty liver Female Females Fibrosis Hepatology Humans Hypertension Inflammation Infusion Iron Liver Liver - diagnostic imaging Liver - drug effects Liver cirrhosis Liver Cirrhosis - diagnostic imaging Liver Cirrhosis - drug therapy Liver Cirrhosis - physiopathology Liver diseases Magnetic resonance Magnetic resonance imaging Magnetic Resonance Imaging - methods Male Medical imaging Medical treatment Medicine Medicine and Health Sciences Middle Aged NMR Non-alcoholic Fatty Liver Disease - diagnostic imaging Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - physiopathology Nuclear magnetic resonance Pectins - therapeutic use Protective Agents - therapeutic use Randomization Reproducibility Research and Analysis Methods Resonance Risk factors Statistical analysis Stiffness Systematic review Treatment Outcome Ultrasonic testing Ultrasonography - methods |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hnLggyquBAgNCAg5uba-9ax_DowSkFqklqDfL-zC1lNgRdiqVP8jfYmbtWDWqVA4ckx1v4nmPPfMtY69MSmCnKWZumudeVBTWU2EqvVhwyzFApdzhdB8di_ki-nIWn1056ot6wjp44I5xB1HObaJsmJpIRqQtKhc2iI3mQgZR4ZBAMeZti6nOB6MVC9EPynEZHPRy2V_Xld2nd29-HI0CkcPrH7zyZL2sm-tSzr87J6-EosO77E6fQ8Ks--877Jat7rGd3kobeNNDSb-9z34vWup9vYS8MnCBZXGHyn0JdQEtStECVv9eWV3k1MUOS2rSgAIr6LopGyhX7ggjWNWGsnWsqaGtoccHt2AJfSLXbrNPJ97RB88Poayg2Sh6uNMAPeOF49np3P28Gw2j7Yb9uxFJyGF9jrHUCwHjpqlX5S9rYDuxCe5YkQdscfjx2_u51x_d4GmRhq2nudQoJ51ESnAfc0xupDHKN7l1CPqCkNIioZTmocIUR6RJonnhF9YE0pchf8gmyAC7y0CLxEp0LFKKIuJhrITyrcYPqBJWpWrK-FaOme5xzel4jWXmXtZJrG86sWQk_ayX_pR5w1XrDtfjBvp3pCIDLaFyuy9QV7NeV7ObdHXKnpOCZd2I6-BbslmMt4d1s4yn7KWjIGSOilp_fuSbpsk-f_3-D0SnJyOi1z1RUSM7UB26cQu8J0L8GlHujSjRv-jR8i6Zw5YrTRYSHhQmwinHK7cmcv3yi2GZNqV2vsrWG0cTYGaYEM2jzqIGznIqOjBvnTI5srUR68crVXnugNGFS7aix_9DVk_YbcyNXWuQL_fYpP25sU8x_2zVM-dq_gCW6YWH priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdGkRAviI2PFQYYhAQ8pErjxE4eECofYyB1SBtFe4tix9kitUlp0onyD_Jvcec4EUHl47Hx2U0uvvPv4vPvCHmaRkh2GgFyUyxx_CzTjvQi4QScaQYLVMQMT_f0mB_N_I9nwdkOaWu2WgVWW0M7rCc1W81H375uXoHBvzRVG8S47TRaloUe4c4awJAr5CqsTQJNdep3-wpg3ZzbA3R_6tlboAyPf-etB8t5WW2Dor9nVP6yRB3eJDcstqSTZjLskh1d7JFrU7t7vkd2rSFX9Lllm35xi_yY1Zgeu6FJkdJLiJwb4u4NLTNaw4vWtCgLJy8uE0x0p3PM46AZBNlllVc0X5gqR3RRpgjoIeymdUkthbimGgkqEmUGe3_iTN86rkfzglZrid9_Koqfgenx5PTI_L05PYbDdeM3pyhpQpcXsNw6HoWlNS0X-Xed0vZQJzWVR26T2eG7z2-OHFvdwVE88mpHMaESrlXoS85cgKEsFWkq3TTRhmSfI5maz6VUzJOAgngUhoplbqbTsXCFx-6QAShA7xOqeKgF-B4heOYzL5BculrBDy9KtYzkkLD2lcbKUp9jBY55bPbzBIRAzRuKcSLEdiIMidP1WjbUH_-Qf42zpZNF4m5zoVydx9YPxH7CdCg13JgvfHR-EnQwDlLFuBj7GQzyCOda3JyC7dxPPAng8SC0FsGQPDESSN5RYHbQebKuqvjDpy__IXR60hN6ZoWyEtQB06E5kQHPhKRgPcmDniS4INVr3kfLaLVSxR5SRgFWjhj0bK1le_PjrhkHxYy_QpdrIzMG8BiizN3GuDrNMoxLANoOieiZXU_1_ZYivzDc6dzgMf_e32_rPrkOwNjkBbnigAzq1Vo_APBZy4fGn_wEYl-GMQ priority: 102 providerName: Scholars Portal |
| Title | Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30192782 https://www.proquest.com/docview/2100861593 https://www.proquest.com/docview/2101266893 https://pubmed.ncbi.nlm.nih.gov/PMC6128474 https://doaj.org/article/4a3e8be29d4749638ba6e15dc36714f4 http://dx.doi.org/10.1371/journal.pone.0203054 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9RAEN8oJMYXI_jBKeJqTNSHQtttd9snAwicJofmEMNb0_0oNIH2pD0S_Af9t5zZ7lVriPrS5G6n23Z352t35jeEvNIpgp2mYLkplntRURhPhqnwYs4MAwWVMovTPTnk4-Po40l84jbcGhdWuZCJVlDrWuEe-VaIKDSgflP2bvbNw6pReLrqSmjcJssIXYYhXeKkd7iAlzl36XJMBFtudjZndWU28QTOj6OBOrKo_b1sXpqd181Nhuef8ZO_KaT9--SesyTpdjf1K-SWqVbJnYk7K18lK45tG_rGYUu_fUB-HLcYDHtN80rTK_CTO5jua1oXtIVpNbSqK6-srnIMa6fnGLVBC3Cp66ZsaHlhaxrRi1qj-Q5ONm1r6gDDDTUIR5Er29nB1Ju89_yQlhVt5hJ3exqKm770cPtobB9vc8Wwu77_LmeS5nR2BsrVCykoUl1flN-NposUTmrrjDwkx_t7X3bHnqvl4Cmehq2nmFA5NyqJJGc-GJ1MC62lr3NjIfU5QqdFXErFQgk2D0-TRLHCL4wOhC9C9ogswQCYNUIVT4wASSMELyIWxpJL3yj4EabayFSOCFtMaaYc0DnW2zjP7OmdAIenm6EMF0LmFsKIeP1dsw7o4x_0O7haelqE6bZ_1JenmeP6LMqZSaSBF4tEhKJOwhgEsVaMiyAqoJPnuNayLue1FzbZdgyfB460iEfkpaVAqI4KY4FO83nTZB8-ff0PoqPpgOi1IypqGA5YDl3-BXwTQoANKNcHlCBw1KB5DTljMSpN9os14c4Ft9zc_KJvxk4xvq8y9dzSBGAqJkjzuGOufmQZeiFgyI6IGLDdYOiHLVV5ZpHSubW-oid_f62n5C6YwTYKyBfrZKm9nJtnYGq2csPKE7gmuwFe9w82yPLO3uHn6YbdvIHrJEp-AlVehYE |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRQIuiJZHA4UuCAQc3Dpeezc-IFQoJaVNkdqmys14H24tpXaok6Lwo_gb_C1m1g8wqoBLj_GON_bs7Dy8M98Q8kyHCHYaguemWOz4SWIc6YXCCTgzDAxUyCxO92Cf94f-x1EwWiDf61oYTKusdaJV1DpX-I18w0MUGjC_IXsz-eJg1yg8Xa1baJRisWvmXyFkK17vbMH6Pve87fdH7_pO1VXAUTz0po5iQsXcqJ4vOXPB_WFaaC1dHRsL7s4RxMvnUirmSbC-POz1FEvcxOiucAUCHYDKvwaG18UdJUZNgAe6g_OqPI-J7kYlDeuTPDPreOLnBn7L_NkuAY0tWJyM8-IyR_fPfM3fDOD2bXKr8lzpZilqS2TBZMvk-qA6m18mS5WaKOjLCsv61R3yYzjF5Ns5jTNNLyAuL2HB5zRP6BTEyNAsz5w0u4gxjZ6OMUuEJhDC50Va0PTM9lCiZ7nGcAGCejrNaQVQbqhB-ItY2ck-HDiDLcf1aJrRYibx61JB8SMz3d887Nu_t7VpOF0zf1mjSWM6OQVj7ngUDLfOz9JvRtO6ZJTaviZ3yfBKVvkeWQQGmBVCFe8ZAZpNCJ74zAskl65R8MMLtZGh7BBWL2mkKmB17O8xjuxpoYAAq1yhCAUhqgShQ5zmrkkJLPIP-rcoLQ0twoLbC_n5SVRpmciPmelJAw_mCx9VqwQedAOtGBddP4FJ1lDWorLGtlFu0WYArweBuwg65KmlQGiQDHOPTuJZUUQ7n47_g-jwoEX0oiJKcmAHiENZ7wHvhJBjLcrVFiUoONUaXsGdUXOliH6pAriz3i2XDz9phnFSzCfMTD6zNF1wTXtIc7_cXA1nGUY94Dh3iGhtuxbr2yNZemqR2bn19vwHf3-sNXKjfzTYi_Z29ncfkpvggtsMJFesksXp-cw8Ajd3Kh9b3ULJ56tWZj8BOFu8bA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemIU28IDb-rDCYQSDgIVsaJ3bzgNBgjJbRgjaK9hbiP9kqbUlZ2qHx0fgCfC3uHCcQNAEve2x8cRP7_Lu7-O5nQh7pGMlOY_DcFEu9MMuMJ4NYeBFnhoGBipnl6R6OeH8cvj2IDhbI97oWBtMqa0y0QK0Lhd_INwNkoQHzG7PNzKVFfNjeeTH94uEJUrjTWh-nUanIrjn_CuFb-XywDXP9OAh2Xn981ffcCQOe4nEw8xQTKuVG9ULJmQ-uENNCa-nr1Fiid46EXiGXUrFAgiXmca-nWOZnRneFL5D0AOD_imBRF9eYOGiCPcARzl2pHhPdTacZG9MiNxu4--dHYcsU2hMDGruwOD0uyouc3j9zN38zhjvXyTXnxdKtSu2WyYLJV8jS0O3Tr5BlBxklfep4rZ_dID_GM0zEPadprukZxOgVRfg5LTI6A5UyNC9yb5KfpZhST48xY4RmEM4X5aSkkxN7nhI9KTSGDhDg01lBHVm5oQapMFJlO3uz5w23PT-gk5yWc4lfmkqKH5zpaGu_b__e1qlhd03_Vb0mTen0CAy7F1Aw4ro4mXwzmtblo9SecXKTjC9llm-RRRgAs0qo4j0jAOWE4FnIgkhy6RsFP4JYGxnLDmH1lCbKkazjWR_Hid05FBBsVTOUoCIkThE6xGvumlYkI_-Qf4na0sgiRbi9UJweJg5xkjBlpicNPFgoQoRZCWPQjbRiXHTDDDpZR11LqnrbBuiSrQheD4J4EXXIQyuBNCE5LrjDdF6WyeD9p_8Q2t9rCT1xQlkBwwHqUNV-wDsh_VhLcq0lCWCnWs2ruDLqUSmTX7AAd9ar5eLmB00zdoq5hbkp5lamC25qD2VuV4urGVmGERA40R0iWsuuNfTtlnxyZFnaufX8wjt_f6x1sgQwlrwbjHbvkqvgjdtkJF-skcXZ6dzcA493Ju9baKHk82Vj2U8USMCi |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Utility+and+variability+of+three+non-invasive+liver+fibrosis+imaging+modalities+to+evaluate+efficacy+of+GR-MD-02+in+subjects+with+NASH+and+bridging+fibrosis+during+a+phase-2+randomized+clinical+trial&rft.jtitle=PloS+one&rft.au=Harrison%2C+Stephen+A&rft.au=Dennis%2C+Andrea&rft.au=%E2%A8%AF+Martine+M+Fiore&rft.au=Kelly%2C+Matt+D&rft.date=2018-09-07&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=13&rft.issue=9&rft.spage=e0203054&rft_id=info:doi/10.1371%2Fjournal.pone.0203054&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |